Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study.
20 auth. J. Ledermann, R. Shapira-Frommer, Alessandro D Santin, A. Lisyanskaya, S. Pignata, I. Vergote, Francesco Raspagliesi, G. Sonke, Michael J. Birrer, Diane Provencher, ... J. Sehouli, N. Colombo, Antonio González-Martín, A. Oaknin, P. Ottevanger, V. Rudaitis, R. Cristescu, J. Kobie, Jane Ruman, Ursula A. Matulonis